Amedisys - AMED Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings or view top-rated stocks.

14 brokerages have issued 12 month price targets for Amedisys' stock. Their AMED share price forecasts range from $85.00 to $180.00. On average, they predict the company's share price to reach $119.53 in the next year. This suggests a possible upside of 62.5% from the stock's current price.
View analysts price targets for AMED or view top-rated stocks among Wall Street analysts.

Amedisys' stock was trading at $83.54 on January 1st, 2023. Since then, AMED shares have decreased by 12.0% and is now trading at $73.55.
View the best growth stocks for 2023 here.

Amedisys saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 1,800,000 shares, a drop of 13.9% from the February 28th total of 2,090,000 shares. Based on an average trading volume of 436,400 shares, the days-to-cover ratio is presently 4.1 days. Currently, 5.7% of the company's stock are sold short.
View Amedisys' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our AMED earnings forecast.

Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings data on Thursday, February, 16th. The health services provider reported $1.16 earnings per share for the quarter, topping analysts' consensus estimates of $1.03 by $0.13. The health services provider earned $562.10 million during the quarter, compared to analysts' expectations of $560.46 million. Amedisys had a net margin of 5.34% and a trailing twelve-month return on equity of 15.44%. The company's revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the company earned $1.18 EPS.

ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include Simplify Health Care ETF (PINK), Harbor Health Care ETF (MEDI), SPDR S&P Health Care Services ETF (XHS), First Trust Health Care AlphaDEX Fund (FXH), SRH U.S. Quality ETF (SRHQ), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), iShares U.S. Healthcare Providers ETF (IHF) and Distillate Small/Mid Cash Flow ETF (DSMC).

Amedisys announced that its Board of Directors has authorized a stock buyback plan on Wednesday, August 4th 2021, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its stock is undervalued.

Amedisys updated its FY23 earnings guidance on Wednesday, February, 15th. The company provided earnings per share guidance of $4.13-$4.36 for the period, compared to the consensus estimate of $4.88. The company issued revenue guidance of $2.244-$2.274 billion, compared to the consensus revenue estimate of $2.36 billion.

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by many different institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (5.42%), Riverbridge Partners LLC (4.70%), Mackenzie Financial Corp (3.20%), Point72 Asset Management L.P. (1.70%), Credit Suisse AG (1.64%) and Millennium Management LLC (1.47%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Richard A Lechleiter, Scott G Ginn and Sharon Brunecz.
View institutional ownership trends.

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMED stock can currently be purchased for approximately $73.55.

Amedisys (NASDAQ:AMED) has a market capitalization of $2.39 billion and generates $2.22 billion in revenue each year. The health services provider earns $118.61 million in net income (profit) each year or $3.64 on an earnings per share basis.

The company employs 20,000 workers across the globe.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163.